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Cautious Approach to Soft Tissue Sarcoma
Yields More Favorable Outcomes
by Dawn Chalaire

necessary to get optimal help for the patient are
sometimes burned."
correct and timely diagnosis is the
The American Cancer Society estimates that in 1999
crucial first step in the treatment of
about 7,800 new cases of soft tissue sarcoma will be
diagnosed in the United States and 4,400 Americans
any disease, but for patients with
will die of the disease. The 5-year survival rate ranges
soft tissue sarcoma, how the diagfrom about 15% for patients with metastatic disease to
nosis is established can be as
about 90% for those with small, localized lesions.
Unfortunately, only about 50% of soft tissue sarcomas
important as when it is made. According to
are
identified in this early stage, in part because superfiRnbert Benjamin, M.D., chairman of the Departcially located soft tissue sarcomas are often mistaken for
ment ofMelanoma/Sarcoma Medical Oncowgy
lipomas, which are benign growths of fatty tissue that
usually require
at The University
no treatment.
of Texas M. D.
"Those
Anderson Cancer
patients who
were initially felt
Center, the initial
to have lipomas
approach to a soft
usually have the
tissue lesion can
most treatable
sarcomas that
have a major
could be cured
impact on a
by surgery alone
patients wngin 80- 90 % of
patients. Yet, the
term outcome.
sarcoma
sits in
"Sarcomas are
Removing an adequate margi,n of surrounding tissue during excisional
place
until
it
very rare tumors,"
biopsy of a soft tissue sarcoma is often difficult, as evidenced fry the photographs
either
starts
to
Dr. Benjamin exabove. The photo at kft shows a soft tissue sarcoma on a patient's upper arm
grow
or
metastaplained, "and in
that recurred just above a transverse biopsy scar. To remove the recurrent
sizes, and then
the course of making
tumor and achieve a wide margi,n around the initial biopsy, a much more
the cure rate
a definitive diagnosis,
complicated procedure involving the removal of a large area of tissue was
the bridges that are
(Cont'd on next page)
required (right) .

Cautious Approach to Soft Tissue Sarcoma
( Continued from page 1)

To achieve an adequate margin, a
large circle of tissue had to be removed
around the transverse biopsy scar on
this patient's arm. To close that wound,
additional tissue along the length of
the arm also had to be removed.

goes way, way down," Dr. Benjamin
said.
That scenario can be avoided;
while the two types of tumors may
look and feel similar, fat has peculiar
characteristics that make it easily
distinguishable on computed tomographic (CT) or magnetic resonance
imaging scans.
Ironically, the aggressive pursuit
of a diagnosis can also be harmful.
For example, an inappropriate or
poorly planned excisional biopsy may
leave tumor cells behind and prevent
the use of state-of-the-art treatment
such as preoperative chemotherapy,
radiation therapy, or both, followed
by definitive surgery.
Patients with high-grade tumors
that are larger than 5 cm in diameter
routinely undergo preoperative
chemotherapy to kill any subclinical
metastases and to shrink the primary
tumor. Such treatment makes surgery
easier to perform and recurrence
less likely.
"We have refined the chemotherapy for soft tissue sarcomas
considerably over the last 5-10 years,"
Dr. Benjamin said. "For patients who
present with extremity sarcomas, we
now have chemotherapy regimens
using fairly high doses of Adriamycin
( doxorubicin) and ifosfamide that
will produce tumor regression in
about 80% of patients. Much of the
2 / MD Anderson OncoLog

The inflammation around this crossshaped biopsy scar on a patient
with synovial sarcoma of the patellar
tendon denotes infection. The patient
later had to have an above-knee
amputation.

The drawing above shows
the minimal tissue disruption
that occurs in a subsequent surgery
when the initial biopsy is parallel to
the long axis of a limb.

general oncology literature
speaks of sarcoma resistance
to chemotherapy, but in
appropriately selected
patients and with appropriately intense treatment, we
find that most patients
benefit from it."
The effectiveness of
chemotherapy is evaluated
by measuring the tumor,
but this cannot be done if
Raphael Pollock,
Robert Benjamin,
the majority of a tumor
M.D., Ph.D., head of
M.D., chairman of
has been removed during
Division of Surgery
Department of
excisional biopsy. Likewise,
and chief of Section of
Melanoma/Sarcoma
if the bulk of a tumor has
Soft Tissue Sarcomas
Medical Oncology
been removed, preoperative
radiation therapy may no longer be
According to Dr. Pollock, if the
possible for the patient, even though
sarcoma is in an extremity, as 70%
it may have been the best option.
are, the biopsy incision should be
After surgery the dose of radiation
parallel to the long axis of the limb.
required for tumor control increases, If it is, definitive surgery can include
as does the total field size of the area
the biopsy scar in an elliptical en bloc
that must be treated.
resection. However, if the biopsy
Poorly designed biopsies can also
incision is perpendicular to an
complicate subsequent surgery and
extremity's long axis, a much wider
cause larger amounts of tissue to be
area of tissue must be removed to
removed to control recurrence. An
close the wound p roperly.
inappropriate biopsy "can make all
"If we use additional techniques
the difference in the world" in how
like radiation therapy after the
he is able to treat a patient, said
surgery, the total field size, of necesRaphael Pollock, M.D., Ph.D., head
sity, must be considerably enlarged
ofM. D. Anderson's Division of
to accommodate the larger tissue
Surgery and chief of the Section
space that's been violated. So the
of Soft Tissue Sarcomas in the
appropriate biopsy is critical," Dr.
Department of Surgical Oncology.
Pollock said.

----+-l- PROTOCOLS -+-----------1-Sarcoma/Osteosarcoma Clinical Trials
Clinical trials currently in progress at The
University of Texas M. D. Anderson Cancer
Center include the following for patients
with sarcoma or osteosarcoma.

I

will not be evaluable for histological
response. In addition, patients who have
low-grade osteosarcoma, parosteal or
periosteal carcinoma, radiation-induced
sarcoma, or osteosarcoma in premalignant bony lesions (e.g ., Paget's disease)
may not take part. Patients who have
received treatment fo r another malignancy are also ineligible for the study.

• Trial of doxorubicin, cisplatin , and
methotrexate with and without
ifosfamide , with and without muramyl
tri peptide phosphatidyl ethanolamine
(MTP-PE) for treatment of osteosarcoma (CCG94-7921 ). Physician:
Norman Jaffe, M.D.
Study participants must have malignant high-g rade osteosarcoma of bone
diagnosed no more than 1 month before
entering the study. They must have
normal organ function , adequate cardiac
fu nction , no history of pericarditis or
myocarditis, and no previous chemotherapy or radiation therapy. Patients
who had a biopsy sample taken from
the primary or metastatic areas for
diagnosis may take part; those who had
a complete or partial resection at the
time of diagnosis may not take part.
Patients who have undergone ablative
surgery may participate, although they

• Actinomycin-O and vincristine with or
without cyclophosphamide and
rad iation therapy for newly diagnosed
patients with low-risk embryonal/
botryoid rhabdomyosarcoma (CCG99O9602) . Physician: R. Beverly Raney,
Jr., M.D.
The chemotherapy drugs actinomycin-D, vincristine, and cyclophosphamide will be given on an outpatient
basis. Patients who do not receive
radiation therapy will return to M. D.
Anderson Cancer Center up to once a
week for 12 weeks; those who do
receive radiation therapy will return
every weekday for 3-5 weeks. Chemotherapy may be given by a family

Furthermore, if hemostasis is
not adequately maintained during
excisional biopsy, the entire extremity is placed at risk for tumor dissemination, and, in rare instances, a
much more radical resection, such
as amputation, may be required to
control disease.
In most cases, problems stemming
trom a biopsy can be avoided li a less
drastic method is used for diagnosis.
Sarcomas can usually be diagnosed by
needle biopsy such as fine-needle
aspiration (FNA) . FNA is less invasive
and less painful than other biopsies
and can produce results in 2- 3 hours.
However, FNA requires expertise in the
placement of the needle and the ability
to make a diagnosis from the appearance of individual cells. To ensure that
tumor cells are sampled, imaging
techniques such as CT and sonography
can be used to guide placement of the
needle into the tumor. Image-guided
FNA, said Dr. Pollock, "is capable of

giving us the pathologic diagnosis for
almost all sarcoma patients whom we
treat. It's actually very rare that we
end up needing to do excisional or
incisional biopsies."
In the rare instances that require
excisional biopsy, it can be effective
if the tumor is small and if the tumor
and a wide margin of surrounding
normal tissue are removed. u ntortunately, many sarcomas may appear
to be encapsulated when they are
actually surrounded by a pseudocapsule of normal tissue compressed
by the sarcoma's rapid growth. Dr.
Pollock said that removal of an
apparently encapsulated tumor leads
to local recurrence in 90% of cases
because the sarcoma sends tentacles
of cells out through the pseudocapsule. "So if you just enucleate the
tumor, you're leaving those tentacles
of cells behind and not treating
them in any way," he said. "They'll
promptly grow out as tumors them-

physician , but radiation therapy should
be given only at M. D. Anderson.
Patients above 21 years of age having
embryonal rhabdomyosarcoma (EMB), the
botryoid or spindle-cell form of EMB, or
embryonal ectomesenchymoma and who
have not received treatment may take part
in this study. Those having tumor-involved
regional lymph nodes or a primary site
other than the orbit may not participate.
• Topotecan and cyclophosphamide
followed by multimodal, multiagent
therapy for children and adolescents
with newly diagnosed stage IV/clinical
group IV rhabdomyosarcoma, an IRS-V
pilot (CCG96-D9501 ). Physician:
R. Beverly Raney, Jr. , M.D.
To be eligible for this study, patients
must be under 21 years of age and have
bidimensionally measurable, pathologically proven rhabdomyosarcoma or
undifferentiated sarcoma. Patients must
also be registered on the study within 42
days of the definitive diagnosis. Women
who are pregnant or breast-feeding may
(Continued on page 4)

selves, which is why you need a
margin around the tumor."
Dr. Benjamin recommended that
patients who have a nonlipomatous
soft-tissue lesion (as determined by
imaging) greater than 5 cm in
diameter and deep in the superficial
fascia of an extremity be referred to
a center that specializes in FNA and
other needle biopsy ct1agnost1c
techniques. This will enable the
planning of definitive surgery or
multidisciplinary treatment if sarcoma is diagnosed. The same rule
of thumb applies to patients with
retroperitoneal masses, which are
almost always malignant.
"The best solution is, if you see a
mass that might be a sarcoma, refer
it to a sarcoma center," Dr. Benjamin
said. •
FoR MORE INFORMATION, contact Dr. Benjamin
at (713) 792-3626 or Dr. PoUock at (713)
792-6928.
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---lt-----PROTOCOLS~lr---(Continued from page 3)
not take part. Also, patients must have
had no previous chemotherapy or
radiation therapy.
• Evaluation of paclitaxel in the treatment
of recurrent or persistent leiomyosarcoma of the uterus (GOG 131-C).
Physician: Thomas W Burke, M.D.
Patients in this study will return to
M. D. Anderson once every 3 weeks
to receive the chemotherapy drug
paclitaxel (Taxol). To be eligible for the
study, patients must have histologically
proven, measurable, recurrent or
persistent leiomyosarcoma refractory
to curative therapy or established
treatments. Patients must have received
unsuccessful therapy, have disease
that is considered incurable, and not
be eligible for a higher priority GOG
protocol. In addition, patients must also
have no side effects from previous
surgery, radiotherapy, or chemotherapy
and no significant infection. Patients
must also wait at least 3 weeks from
their previous therapy to enter the study.
Patients who have abnormal cardiac
conduction must have had stable
disease for the previous 6 months.
Those who have received previous
therapy with paclitaxel or more than one
previous chemotherapy regimen, have a
concomitant malignancy other than of
the skin (except for melanoma), or have
unstable angina or had a myocardial
infarction within the previous 6 months
are ineligible forjhe study.
• A phase I study of preoperative
chemoradiation and intraoperative
radiation therapy in the treatment of
retroperitoneal sarcoma (!095-225).
Physician: Peter W T. Pisters, M.D.
To be eligible for this study, patients
must have cytologically or histologically
proven grade 2 or 3 sarcoma. They must
be at least 18 years of age and have had
no previous abdominal radiation therapy,
no evidence of other serious uncontrolled medical conditions, and normal
renal function. The study chairman may
choose to exclude patients who have a
4 / MD Anderson OncoLog

prior history of malignancy. Patients
must maintain adequate food intake
and be free from nausea and vomiting.
Women must not be pregnant and
should refrain from breast-feeding.
• A phase I study of preoperative concurrent
chemoradiation for high-risk extremity and
trunk soft tissue sarcomas (!097-335) .
Physician: Peter W T. Pisters, M.D.
Patients in this study will return to
M. D. Anderson daily to undergo
radiotherapy. Assessment of the
patient's chemotherapy and dosing will
be done weekly. To be eligible , patients
must have cytologically or histologically
proven , large, resectable soft tissue
sarcoma of an extremity or the trunk.
The sarcoma may be measurable or
nonmeasurable. Patients who have
received previous doxorubicin-based
chemotherapy may take part only if the
total dose was no greater than 450 mg/
m2. Admission of patients who have a
previous history of malignancy to the
study must be approved by the study
chairman. Those who have a history of
previous irradiation to the area of the
primary tumor or the radiation field in
this study, which includes the perineum
and scrotum or vaginal introitus, may
not take part. In addition, patients
having uncontrolled coexisting medical
conditions and women who are pregnant or breast-feeding may not take part.
• A pilot study of intraperitoneal hyperthermic chemotherapy for the treatment
of sarcomatosis and peritoneal mesothelioma (IDP98-176). Physician:
Kelly K. Hunt, M.D.
Patients must have cytologically,
radiographically, or histologically proven
sarcomatosis from soft tissue sarcoma
to participate in this study. The primary
tumor must be intact or have been
resected in a previous surgery. Patients
who underwent previous laparotomy
may not take part for 2-4 weeks after
the surgery. Also, patients who received
previous chemotherapy may not take
part in this study until at least 4 weeks
after therapy. Patients who have ascites
may participate. Those who have

uncontrolled medical problems including
but not limited to diabetes, hypertension, and cardiovascular disease;
ongoing sepsis or chronic infection;
evidence of an impending obstruction on
x-ray images; or known previous toxic
effects of platin um-based chemotherapy
may not take part. Whether patients
having significant cardiac disease or a
history of it take part will be decided by
the principal investigator. Women who
are pregnant may not participate.
• Phase II study of recombinant interferon-alpha and etoposide in patients
with relapsed osteosarcoma (P96-221 ).
Physician: Eugenie S. Kleinerman, M.D.
Patients in this study will receive the
chemotherapy drugs interferon-alpha
and etoposide on an inpatient basis.
Their length of stay at M. D. Anderson
will be either 5 days or 3 weeks. To be
eligible , patients must have a primary
diagnosis of histologically proven
osteosarco ma and must have undergone
previous unsuccessful chemotherapy.
They must also be between 5 and 70
years of age and have a life expectancy
of at least 12 weeks. In addition, patients
must not have received chemotherapy,
immunotherapy, hormonal therapy, or
radiation therapy within 3 weeks of
entering the study, and they must have
recove red from acute toxic effects of
previous therapy. Patients who have
brain metastases may take part if the
metastases have been controlled for
6 months and are not life-threatening.
Patients having a serious intercurrent
illness, such as congestive heart failure
or cardiomyopathy, are ineligible. Also,
women who are pregnant or lactating
may not take part. •
about these clinical
trials, physicians or patients may call the
M. D. Anderson Information Line. Those
within the United States should call (800)
392-1611; those in Houston or outside
the United States should call (713) 7926161. Visit the M . D. Anderson Cancer
Center clinical trials web site at http:/I
www. clinicaltrials. org for a broader
listing of treatment research protocols.
FOR MORE INFORMATION

Orthopaedic Surgeons Save Limbs, Restore

Fundion for Patients with Bone Tumors
by Dawn Chalaire

t The University of Texas M. D.
Anderson Cancer Center, the successful treatment of primary bone
and soft tissue tumors and bone
metastases is just the begi,nning
of what is often a long relationship between
the Orthopaedic Center and its patients.
"We're very tuned in to the functional outcome of
patients," said Alan Yasko, M.D. , chief of the Section of
Orthopaedic Oncology in the Department of Surgical
Oncology. "Early on, we're con cerned with patient survival, local tumor control, and reconstructive surgery with
minimal risk of complications. Later, long-term survivors
become more of a non-oncologic orthopaedic issue. That's
why our research efforts are focused on trying to restore
limb function with predictable durability."

Alan Vasko, M.D., chief of the Section of Orthopaedic Oncology,
compares a custom-engi,neered pelvic bone replacement made
using stereolithographic techniques with a patient x-ray. Dr.
Yasko 's research includes work in developing injectable bone
graft substitutes to replace currently available substitutes made
from particulates.

In the past, many patients with malignant tumors in
an arm or leg had to have an amputation as part of their
cancer treatment. Now, more than 95% of the patients
treated in the Orthopaedic Center are able to undergo
limb-saving procedures in which sections of tumorinvolved bones and joints are removed and replaced
by prostheses or allografts. Dr. Yasko credits the center's
success to an improved understanding of tumors, better
imaging techniques, and the support of radiologists,
pathologists, and chemotherapists.
"We've had a lot of patients who have been told that
amputation is their only option, and the overwhelming
majority of those don't end up with an amputation,"
Dr. Yasko said. "Because of our experience, we are able
to spare limbs without compromising the overriding
objective of tumor control."
The increasing number of patients who are able to
undergo limb-saving procedures has led to the expansion
of research into new methods of restoring limb function .
Currently, most bone and joint replacements are prosthetic. Dr. Yasko said that prosthetic replacements are
used early in the course of cancer management at M. D.
Anderson because they have an infection rate of less
than 1 %, which means that after reconstructive surgery,
the majority of patients can resume chemotherapy
quickly and with fewer interruptions. Some centers use
osteoarticular allografts obtained from a national bone
bank for reconstruction. The allografts eventually
become incorporated into the native bone, and, unlike
metallic prostheses, they do not become loose over time
or need to be replaced. However, with the allografts,
the risk of infection and complications early in the
postoperative course is fairly significant.
"Therefore, if you do well with the allograft, then
perhaps it is the more favorable approach," Dr. Yasko
said. "However, if you don 't do well, then you get into
a problem with compromising the patient's systemic
therapy. So we have opted to go with the more predictable and lower-risk reconstruction that will restore
function immediately, and then if problems arise, they
will be dealt with after the patients have completed
their chemotherapy course," Dr. Yasko said.
For the past four years, Dr. Yasko has been collaborating
with bioengineers at Rice University in Houston and
mechanical engineers in private industry to develop bone
graft substitutes and techniques for engineering new bone.
In particular, they are investigating the use of injectable,
biocompatible, biodegradable polymers to restore bone
and the use of growth factors and cell transplantation
techniques to help guide bone tissue growth.
The injectable bone graft substitute would be used
to fill irregular defects in bone where a tumor has been
surgically scooped out or to augment healing at tradi(Continued on page 6 )
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Orthopaedic Surgeons Restore Function
(Continued from page 5)

tional graft junctions. It could also replace large segments
of bone by manipulating the growth of new bone tissue.
"One approach of tissue engineering is to try to deliver
to that locale those elements that you need to stimulate new
bone formation. So if you have a proper osteoconductive
scaffold and the necessary cell population and can introduce growth factors that will induce those cells to form new
bone, then you have created a milieu that is ideal for new
bone formation," Dr. Yasko said.
Carrying the concept one step further, the researchers
are also looking at using the polymers they are developing
not only to help bone heal and stimulate new bone
growth but also as delivery vehicles for chemotherapy
agents and antibiotics.
''You can imagine that if we had a material that would
not only restore bone stock but also, at the same time,
deliver chemotherapy agents as a local adjunct and
antibiotics locally to minimize or to help guard against
infection, then we have really addressed three major
problems: local tumor control, early complications
associated with reconstructions, and long-term anatomy
and functional restoration," Dr. Yasko said.
Dr. Yasko and the other researchers are also working
to develop novel methods of reconstruction following
complex pelvic resections, new methods of soft tissue
attachment to optimize function after large-segment bone
resection, and prototypes for "growing" prostheses that
will allow for expansion or lengthening of the prosthesis
without surgery for children who have undergone
resection of tumors in the extremities.
In addition to Dr. Yasko's research in bone reconstruction, orthopaedic surgeons Patrick Lin, M.D., and Kristin
Weber, M.D., are investigating the molecular approaches
to systemic tumor control. The center is in the process of
recruiting a fourth orthopaedic surgeon who has a primary
interest in the spine and sacrum to complement the spine
tumor efforts of the Department of Neurosurgery.
Even as their research efforts expand, the orthoaedic sur eons remain committed to atient service
and are usually able to see patients within 24 hours.
Despite pressures from HMOs and other organizations,
Dr. Yasko said that physicians should not feel obligated
to make a diagnosis before referring patients to M. D.
Anderson. In many cases, a consultation-even a phone
consultation-to get an opinion regarding the best way
to evaluate a patient before referral probably serves
patients best.
"Because of the rarity of the tumors, the majority of
orthopaedic surgeons will not treat or attempt to treat
these tumors. Most of the time, they won't do a biopsy
out of concern that they may compromise the patient's
ultimate care , principally as it relates to whether we can
save an extremity or whether we have to amputate the
extremity," Dr. Yasko said. •
contact the Orthopaedic Center at
(713) 792-6235 or Dr. Yasko at (713) 794-5242.

FoR MORE INFORMATION,
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What's to Eat?
Encouraging children to eat well
for a healthier future
by Alison Ruffin and Vickie Williams

D arewell lazy, carefree days of summer_L--Y it's back-to-school time!
During this schedule-:iuggling time of year, eating
healthy meals can be a challenging assignment for busy
families. Doctors at The University of Texas M . D .
Anderson Cancer Center want to ensure that parents
and students learn one lesson: there is an important
link between good nutrition and good health.
"We can reduce a child's risk for cancer in the future
by teaching him or her to make healthy food choices
today, which, we hope, will become a good h abit that
will last for a lifetime," says Tom Baranowski, Ph.D.,
a behavioral nutrition researcher at M. D. Anderson.
Of particular interest is the recent finding that eating
5 servings of fruits and vegetables per day may reduce by
about 30% the risk for lung, prostate, bladder, esophageal,
colorectal, and stomach cancers. Most children consume
less than 2.5 servings of these foods per day.
Bernard Levin, M.D., vice . - - - - - - - - -----.......,
president for cancer prevenNutrition
tion at M. D. Anderson, says
Recommendations
learning to appreciate the
for Cancer Prevention
health benefits of eating well
(American Cancer Society)
should begin at an early age.
II' Maintain a desirable
"It's important for children
weight.
to know that, in addition to
II' Eat a varied diet.
providing long-term health
II' Eat a variety of fruits
benefits, nutritious meals
and vegetables daily.
and snacks taste good and
II' Eat high-fiber foods, such
are enjoyable to eat," he
as whole-grain cereals,
explains. "With a little
breads, pasta, fruits, and
planning, 5 or more daily
vegetables.
~ ~
1.-1
servin s of fruits and ve Reduce total fat intake. -..~~,.,..
etables can be incorporated
II' Limit consumption of
easily into a family's diet."
alcohol.
Families need to evaluII' Limit consumption of
ate and restructure their
salt-cured, smoked, and
diets to ensure that everynitrite-cured foods.
one is getting the proper
nutrition, urges Dr.
Baranowski. Children should be included in meal
planning and preparation. "Encourage children to get
in the kitchen and mix something up," he says. "Also
be sure they take at least one bite of what might be
a new food for them."
Replacing high-fat, high-sugar foods with nutritionpacked alternatives that will provide long-term health
benefits is a family project that will earn everyone an A+. •
of the brochure "M. D. Andersons Road Map
to Cancer Prevention," call (713) 794-4237.
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Breast Cancer:
Understanding the Risks
mong North American women, breast cancer is the most
common cancer (other than skin cancer) and is the
second leading cause of cancer-related deaths, after lung
cancer. No one knows exactly why breast cancer strikes
some women and not others, but several risk factors may increase
the likelihood. These risk factors can be divided into two
categories: controllable and uncontrollable.

A

Controllable risk factors

Uncontrollable risk factors

High-fat, high-calorie diet: Studies
show that women in populations
that consume a high-fat diet are
more likely to die of breast cancer
than women in populations that
consume a low-fat diet. Obesity has
been suggested as a breast cancer risk
factor in several studies, and more
recent data point to the risks associated with a high-calorie diet.
Alcohol: Although moderate
alcohol consumption (up to two
drinks per day) has been shown
to decrease the risk of coronary
heart disease in middle-aged adults,
women who have an average of one
alcoholic drink per day have a
slightly higher risk of breast cancer
than nondrinkers, and the risk
increases with the amount of
alcohol consumed.
Sedentary lifestyle: Studies indicate
that strenuous exercise in youth
might provide life-long protection
against breast cancer and that even
moderate physical activity as an adult
can lower breast cancer risk.
Age at first live birth: Having the
first full-term pregnancy after age
30 or never giving birth can increase
the risk of breast cancer.
Hormone replacement therapy:
Studies suggest that long-term hormone replacement therapy (HRT)
may slightly increase a woman's risk of
developing breast cancer; however,
HRT also has important benefits,
including helping to prevent osteoporosis and possibly reducing or
postponing the risk of having a heart
attack or stroke.

Age: Simply getting older increases a woman's chances of developing breast cancer. Over 75 % of
women in whom breast cancer is
diagnosed are over the age of 50.
Family history: Having a mother,
daughter, or sister with breast cancer
increases a woman's risk of developing the disease. Also, breast cancer
that is linked to a genetic cause may
occur at a younger-than-average age.
Age at first menstrual period:
Women who began menstruating
before age 12 have a slightly increased risk of breast cancer.
Previous breast biopsies: Women
who have had benign (noncancerous) breast disease that required
a biopsy have an increased risk of
breast cancer, especially if the biopsy
showed a change in breast tissue
known as anaplasia. Not all conditions leading to biopsy contribute
to an increased risk, however.
Other breast diseases: Noninvasive
cancers such as ductal carcinoma in
situ and lobular carcinoma in situ
are associated with an increased risk
of invasive breast cancer.
Radiation therapy: Women who
received radiation therapy to the
chest for Hodgkin's disease or other
types of cancer, especially at a young
age, are at increased risk for developing breast cancer.

Detection and prevention
Just because you have some risk
factors for breast cancer does not
mean that you will develop the
disease; the known risk factors

account for only a small fraction
of all cases of breast cancer.
There are steps that you can take
to lower your risk and ensure that
breast cancer will be detected at a
more curable stage. Your doctor
will counsel you about your personal
breast cancer risk factors and recommend a schedule of screening examinations.
Beginning at age 40, all women
should have a mammogram every
year. All women should do a monthly
breast self-examination as well as have
an annual clinical breast examination
by a health professional. If you have
a strong family history of breast
cancer, you may wish to be tested for
an inherited gene mutation. If a
mutation is found, more frequent
exams to monitor the early signs of
cancer can be scheduled.
If you are at high risk for developing breast cancer, you may be interested
in participating in a multinational
breast cancer prevention trial, the
study of tamoxifen and raloxifene
(STAR). To participate, you must be
at least 35 years old, postmenopausal,
and have an increased risk of breast
cancer as determined by a risk
assessment form .

For more information
about the STAR program
or to participate, please
call (713) 792-8064 or
(800) 392-1611. •

For more information, contact
your physician or contact the
M. D. Anderson Information Line:

({) (800) 392-1611 within
the United States, or

({) (713) 792-6161 outside
the United States.
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High-Dose Chemotherapy Deserves More Study
Aman Buzdar, M.D.
Professor, Department of
Breast Medical Oncology
A series of phase III
trials that cast doubt
on the effectiveness
of high-dose chemotherapy (often
referred to as bone
marrow transplantation) may leave
breast cancer
researchers in a
catch-22: At a time
when continuing research is critical for
defining the role of high-dose chemotherapy, recruiting patients and convincing insurance companies to pay for
clinical trials may become more difficult.
High-dose chemotherapy-doses that
are 5 to 30 times higher than standard
doses- supported by bone marrow or
peripheral blood stem cell transplantation
is considered an established therapy for
many tumor types. In several early phase I
and II studies, high-dose chemotherapy
produced a higher complete remission
rate than standard-dose regimens in
patients with metastatic breast cancer,.
and the tumors completely disappeared
in 30- 50% of patients whose cancer was
already responding to standard therapy.
Once the data from the early studies
became available, some hospitals began
using high-dose chemotherapy as standard care for breast cancer as if its value
had been proven . The remissions were
short-lived, however, and four of five
phase III studies presented earlier this
year at the annual meeting of the Ameri8 I MD Anderson OncoLog

can Society of Clinical Oncology
showed no significant difference in
survival rates among patients given
high-dose chemotherapy and tho e
given standard-dose chemotherapy.
The bottom line is that high-do e
chemotherapy is still under inve tigation, and it should be administered only
under the strict guidelines of a research
protocol. I can say emphatically that at
M. D. Anderson Cancer Center, highdose chemotherapy is not con idered
standard care for any subset of patie nts
with breast cancer in any stage.
We, however, will continue to inve tigate the role of high-dose chemotherap
in breast cancer treatment. The aim of
our phase II studies are to: (1) improv
treatment safety, (2) increase th
duration of remissions, (3) develop
novel drugs and novel treatment
combinations, and (4) identify a ub t
of patients who can benefit from highdose chemotherapy. If we have encouraging results from these studie , we
will begin phase III studies to compare
high-dose chemotherapy with tandard
chemotherapy.
I tell every patient with brea t cancer
who asks about high-dose chemotherap
that it is still a research treatment.
However, we cannot make progress
unless women are willing to participate
in research studies, so I encourage
patients who understand the risks to
participate in studies that are well
designed and well controlled. With
their help, I am optimistic that in the
next few years, we will develop treatments that will result in better disease
control for patients with breast cancer.
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